| Lorraine Schwartz, LPN | |
|
261 Connecticut Dr, Ste 5, Burlington, NJ 08016-4177 | |
| (800) 950-6066 | |
| (609) 387-7540 |
| Full Name | Lorraine Schwartz |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 261 Connecticut Dr, Burlington, New Jersey |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598931917 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 26NP05411900 (New Jersey) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Lorraine Schwartz, LPN 909 S Concourse, Keyport, NJ 07735-5353 Ph: () - | Lorraine Schwartz, LPN 261 Connecticut Dr, Ste 5, Burlington, NJ 08016-4177 Ph: (800) 950-6066 |
News Archive
Kinaxo Biotechnologies GmbH announced today that it has entered into a two-year collaboration with Boehringer Ingelheim. Under the agreement Kinaxo will apply its new platform technologies to studies on drug mode of action and target identification. Financial details of the agreement were not disclosed.
The cost of cancer care is threatening to bankrupt our healthcare system. New drugs are prolonging life, but at staggering costs. This coupled with aging baby boomers and an increasing population mean the U.S. will spend $173 billion annually on cancer care by the year 2020. This trend is not sustainable; however, there are evidence-based ways to maintain or improve the quality of care while saving money for the new therapies being discovered every day.
Onconova Therapeutics, Inc., and SymBio Pharmaceuticals Limited announced today that they will collaborate to develop and commercialize rigosertib in Japan and Korea. Onconova is conducting late-stage clinical trials with rigosertib (ON 01910.Na) in the U.S., Europe and India for the treatment of Myelodysplastic Syndromes (MDS) and solid tumors.
Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, today announced special commercial licensing terms to facilitate rapid access to its cGMP-compliant CHOSOURCE platform for the development or production of therapeutic proteins, diagnostic assay components or vaccines relating to COVID-19.
ExonHit Therapeutics today reported the signing by Allergan, Inc. and Bristol-Myers Squibb Company of a global exclusive license agreement for the development and commercialization of EHT/AGN 0001 (AGN-209323), ExonHit's lead compound from the most advanced program of its collaboration with Allergan.
› Verified 8 days ago
Denise Mongiello, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 261 Connecticut Dr, Suite 5, Burlington, NJ 08016 Phone: 800-950-6066 | |
Antonea Kouassi, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 261 Connecticut Dr, Suite 5, Burlington, NJ 08016 Phone: 800-950-6066 | |
Kenneth Deane Perren, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 261 Connecticut Dr Ste 5, Burlington, NJ 08016 Phone: 800-950-6066 | |
Arlena Seegers, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 261 Connecticut Dr, Suite 5, Burlington, NJ 08016 Phone: 800-950-6066 | |
Sherene Carter, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 261 Connecticut Dr, Suite 5, Burlington, NJ 08016 Phone: 800-950-6066 | |
Margaret M Bryski, LPN Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 261 Connecticut Dr, Burlington, NJ 08016 Phone: 800-950-6066 | |
Valorie Scott, Licensed Practical Nurse Medicare: Not Enrolled in Medicare Practice Location: 504 Linden Ave, Burlington, NJ 08016 Phone: 800-950-6066 |